These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23680209)

  • 1. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
    Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
    J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 4. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
    Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
    Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential new risks of lenalidomide.
    Gertz MA; Buadi FK
    Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
    Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
    Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zeroing in on cereblon.
    Heaney ML
    Eur J Haematol; 2015 Jul; 95(1):1-2. PubMed ID: 25777766
    [No Abstract]   [Full Text] [Related]  

  • 14. A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
    Xu G; Wang B; Yang M; Qian W
    Int J Clin Exp Pathol; 2015; 8(11):15025-9. PubMed ID: 26823839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe hypocalcemia due to lenalidomide.
    Kong S; Collet P; Marotte H; Thomas T
    Joint Bone Spine; 2015 Oct; 82(5):380-1. PubMed ID: 25726251
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
    Gavriatopoulou M; Kastritis E; Ntanasis-Stathopoulos I; Fotiou D; Roussou M; Migkou M; Ziogas DC; Kanellias N; Terpos E; Dimopoulos MA
    Blood; 2018 Jan; 131(4):464-467. PubMed ID: 29167176
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide--the phoenix rises.
    List AF
    N Engl J Med; 2007 Nov; 357(21):2183-6. PubMed ID: 18032768
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of multiple myeloma by immunomodulatory drugs].
    Hata H
    Rinsho Ketsueki; 2011 Oct; 52(10):1485-95. PubMed ID: 21971225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.